Model-based cost-effectiveness analysis of [18F]FDG PET/CT early into therapy with immune checkpoint inhibitors: Tackling pseudoprogression in unresectable cutaneous melanoma patients
Model-based cost-effectiveness analysis of [18F]FDG PET/CT early into therapy with immune checkpoint inhibitors: Tackling pseudoprogression in unresectable cutaneous melanoma patients. // The EANM Journal. – URL: https://www.sciencedirect.com/science/article/pii/S3051292126002149?dgcid=rss_sd_all
Model-based cost-effectiveness analysis of [18F]FDG PET/CT early into therapy with immune checkpoint inhibitors: Tackling pseudoprogression in unresectable cutaneous melanoma patients. The EANM Journal. https://www.sciencedirect.com/science/article/pii/S3051292126002149?dgcid=rss_sd_all
“Model-based cost-effectiveness analysis of [18F]FDG PET/CT early into therapy with immune checkpoint inhibitors: Tackling pseudoprogression in unresectable cutaneous melanoma patients.” The EANM Journal.
@article{article67786,
title = {Model-based cost-effectiveness analysis of [18F]FDG PET/CT early into therapy with immune checkpoint inhibitors: Tackling pseudoprogression in unresectable cutaneous melanoma patients},
journal = {The EANM Journal},
url = {https://www.sciencedirect.com/science/article/pii/S3051292126002149?dgcid=rss_sd_all}
}